AAIC 2012: GE Healthcare (GE) says a Phase 3 trial of [18F]flutemetamol confirms the potential...

|By:, SA News Editor
AAIC 2012: GE Healthcare (GE) says a Phase 3 trial of [18F]flutemetamol confirms the potential of the imaging agent for detecting amyloid plaque, which is associated with Alzheimer's disease. GE plans to file for FDA approval of [18F]flutemetamol later this year. (PR)